Search clinical trials for: Melphalan

Total 767 results

St. Jude Children's Research Hospital

Completed

Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome

United States
Children's Cancer and Leukaemia Group

Completed

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Neuroblastoma
National Cancer Institute (NCI)

Completed

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Colorectal Cancer | Metastatic Cancer

United States
Novartis Pharmaceuticals
Medicines for Malaria Venture

Completed

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Acute Uncomplicated Plasmodium Falciparum Malaria

Thailand, Gabon, Mali, Uganda, Burkina Faso, India, Kenya, Mozambique, Vietnam
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Sarcoma of Pelvis

France
Lynk Biotechnologies Pte Ltd
T&T Family Health Clinic and Surgery, Singapore; Temasek Polytechnic School...

Completed

Transdermal Delivery of Glucosamine to the Synovial Fluid of Male and Female With Knee Osteoarthritis

Osteoarthritis, Knee

Singapore
M.D. Anderson Cancer Center

Completed

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Lymphoma | Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Cigdem Sahinbas YILMAZ
Turkish Society of Hematology Myeloma Study Group

Completed

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Multiple Myeloma

Turkey
Cancer Research UK

Unknown

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Lymphoma
National Cancer Institute (NCI)

Completed

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

Recurrent Melanoma | Stage III Melanoma

United States
Chun-Yao Huang

Unknown

Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

Heart Failure | Atrial Fibrillation | Ivabradine

Taiwan
Gerstein, Hertzel, MD
Heart and Stroke Foundation of Ontario

Completed

The Study of Atherosclerosis With Ramipril and Rosiglitazone

Cardiovascular Disease | Atherosclerosis | Impaired Glucose Tolerance | Isolated Impaired Fasting Glucose
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; GlycoMimetics Incorporated

Completed

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

Multiple Myeloma

United States
Federal State Budgetary Institution, Pulmonology...
Moscow State University of Medicine and Dentistry; Medsi Clinic #1, Moscow

Unknown

Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia (MICOV)

COVID-19 | Viral Pneumonia

Russian Federation
Delcath Systems Inc.

No longer available

Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

Ocular Melanoma | Cutaneous Melanoma | Metastatic Liver Cancer

United States
University of Nebraska
National Cancer Institute (NCI); Genentech, Inc.

Completed

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Sanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaborators

Active, not recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Lymphoma | Leukemia | HIV

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

Leukemia

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Sarcoma | Undifferentiated Pleomorphic Sarcoma | Alveolar Soft Part Sarcoma | Myxofibrosarcoma

United States
Boston Medical Center

Completed

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (MRD)

Multiple Myeloma

United States
Cancer Research UK

Unknown

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Lymphoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States
Wen-Kai Weng

Completed

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Multiple Myeloma | Blood Cancer

United States
Insel Gruppe AG, University Hospital Bern

Recruiting

Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients (TreoMel)

Multiple Myeloma

Switzerland
Barts & The London NHS Trust

Terminated

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) (MEL-CAP)

Castrate Resistant Prostate Cancer

United Kingdom
Amgen

Completed

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

Healthy Participants

United States
Universiti Sains Malaysia
Ministry of Health, Malaysia

Completed

To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients

Diabetes | Impaired Glucose Tolerance

Malaysia
Herbert Irving Comprehensive Cancer Center

Completed

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Amyloidosis

United States
Seagen Inc.

Terminated

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Acute Myeloid Leukemia

United States
Medical Research Council

Unknown

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
PETHEMA Foundation

Completed

GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

Multiple Myeloma

Spain
Mayo Clinic

Withdrawn

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma
M.D. Anderson Cancer Center

Withdrawn

Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts

Multiple Myeloma
Teva Pharmaceuticals USA

Completed

Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions

Healthy

Canada
University Hospital Inselspital, Berne
Mundipharma Medical Company

Completed

Bendamustine and Melphalan in Myeloma (BEB-2)

Multiple Myeloma

Switzerland
Weill Medical College of Cornell University

Completed

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Oncopeptides AB

Terminated

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)

Multiple Myeloma

United States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
FDA Office of Orphan Products Development

Completed

Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis

Amyloidosis
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Arkansas

Withdrawn

A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Completed

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Hematologic Malignancy

United States

Search clinical trials for: Melphalan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations